Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature.

Studies published from January 1966 until October 2000 on the clinical effects of focal neuronal and neuromuscular blockade in post stroke upper limb spasticity were identified. Twelve studies were included and evaluated on 13 methodological criteria. Ten studies on Botulinum toxin type A (BTX-A) treatment were found (of which 4 were randomised controlled trials (RCTs) and 6 were uncontrolled observational studies) as well as one uncontrolled observational study on phenol blockade of the subscapular muscle and one on alcohol blockade of the musculocutaneus nerve. The homogeneity of the patient groups with regard to diagnosis and their comparability with regard to functional prognosis and other sources of bias were generally unsatisfactory. Only two RCTs met predetermined criteria of minimal validity. There is evidence of effectiveness of BTX-A treatment on reducing muscle tone (varying between 0.8 and 2.0 points on the modified Ashworth scale) and improving passive range of motion at all arm-hand levels in chronic stroke patients for approximately 3-4 months. There is also preliminary evidence of a synergistic effect of concomitant electrostimulation. Taking into account a critical maximum dose of 100 MU Botox" (300-500 MU Dysport) for preserving active finger flexion, BTX-A treatment seems to be a safe focal spasmolytic treatment. Effectiveness of BTX-A treatment on improving functional abilities could not be convincingly demonstrated, although two subgroups may be identified that might specifically benefit at a functional level: (1) patients with mild spasticity and a potential for voluntary extensor activity and (2) patients with severe spasticity suffering from problems with positioning and taking care of the affected arm and hand. Larger controlled studies are needed to compare the effectiveness of BTX-A with other focal spasmolytic techniques paying special attention to individual goal assessment, the (duration of) functional benefits, co-treatment and aftercare, side-effects and cost-effectiveness.

[1]  G. Felsenthal.  Pharmacology of phenol in peripheral nerve blocks. A review G. Felsenthal Arch. Phys. Med. Rehab. 55 (1974) , 1975, PAIN.

[2]  M. Botte,et al.  Management of intrinsic spasticity in the hand with phenol injection or neurectomy of the motor branch of the ulnar nerve. , 1987, The Journal of hand surgery.

[3]  A. Rodriquez,et al.  Botulinum toxin injection of spastic finger flexors in hemiplegic patients. , 2000, American journal of physical medicine & rehabilitation.

[4]  J. Pélissier,et al.  Neurolyse chimique à l'alcool (alcoolisation) dans le traitement de la spasticité chez l'hémiplégique. , 1993 .

[5]  R. Fusfeld.  Electromyographic findings after phenol block. , 1968, Archives of physical medicine and rehabilitation.

[6]  E. Elovic,et al.  Chemical Denervation for the Treatment of Hypertonia and Related Motor Disorders: Phenol and Botulinum Toxin , 1997 .

[7]  J. Birns,et al.  Management of Spasticity , 2015 .

[8]  S. Hesse,et al.  Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial , 1998, Clinical rehabilitation.

[9]  R. Young,et al.  Spasticity, disordered motor control , 1980 .

[10]  D. Wade,et al.  Recovery after stroke , 1983, Journal of neurology, neurosurgery, and psychiatry.

[11]  M. Brin,et al.  Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult‐onset spasticity , 1997, Muscle & nerve. Supplement.

[12]  W. Peacock,et al.  The surgical treatment of spasticity , 2000, Muscle & nerve.

[13]  R. Braun,et al.  Spasticity in the upper extremity. , 1974, Clinical orthopaedics and related research.

[14]  K. M. Wood.  The use of phenol as a neurolytic agent: A review , 1978, Pain.

[15]  Werner Poewe,et al.  A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke , 2000, Stroke.

[16]  D. Halpern,et al.  Duration of relaxation after intramuscular neurolysis with phenol. , 1967, JAMA.

[17]  J. Ferro,et al.  Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients , 1997, Clinical rehabilitation.

[18]  S H Pierson,et al.  Outcome measures in spasticity management , 1997, Muscle & nerve. Supplement.

[19]  D. M. Simpson,et al.  Botulinum toxin type A in the treatment of upper extremity spasticity , 1996, Neurology.

[20]  D M Simpson,et al.  Traditional pharmacological treatments for spasticity part I: Local treatments , 1997, Muscle & nerve. Supplement.

[21]  D. Halpern,et al.  Phenol motor point block in the management of muscular hypertonia. , 1966, Archives of physical medicine and rehabilitation.

[22]  T C Chalmers,et al.  A method for assessing the quality of a randomized control trial. , 1981, Controlled clinical trials.

[23]  M. Botte,et al.  Treatment of shoulder deformity in acquired spasticity. , 1999, Clinical orthopaedics and related research.

[24]  J. Benton,et al.  A Physiologic Approach to the Evaluation and the Management of Spasticity With Procaine and Phenol Nerve Block Including a Review of the Physiology of the Stretch Reflex , 1966, Clinical orthopaedics and related research.

[25]  A. Verbeek,et al.  The Effects of Phenol Nerve and Muscle Blocks in Treating Spasticity: Review of the Literature , 1996 .

[26]  A. Magora,et al.  Treatment of spasticity by phenol block. , 1970, Israel journal of medical sciences.

[27]  T K Das,et al.  Effect of treatment with botulinum toxin on spasticity. , 1989, Postgraduate medical journal.

[28]  A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. , 1998, Disability and rehabilitation.

[29]  B. Jabbari,et al.  Botulinum toxin A for spasticity, muscle spasms, and rigidity , 1995, Neurology.

[30]  D. Garland,et al.  Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured adults. , 1984, Archives of physical medicine and rehabilitation.

[31]  N. Mayer,et al.  Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion , 1997, Muscle & nerve. Supplement.

[32]  Wilson Dj,et al.  Evaluation and treatment of the upper extremity in the hemiplegic stroke patient. , 1969 .

[33]  L. Provinciali,et al.  Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. , 2000, American journal of physical medicine & rehabilitation.

[34]  J. G. Benton,et al.  MANAGEMENT OF SPASTICITY BY SELECTIVE PERIPHERAL NERVE BLOCK WITH DILUTE PHENOL SOLUTIONS IN CLINICAL REHABILITATION. , 1964, Archives of physical medicine and rehabilitation.

[35]  J. Keenan,et al.  Phenol nerve and motor point block in spasticity. , 1972, Rheumatology and physical medicine.

[36]  Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles , 1997, Neuroreport.

[37]  R. Hewer.  Rehabilitation after stroke. , 1990 .

[38]  D. Tk,et al.  Botulinum toxin in treating spasticity. , 1989 .

[39]  B. Bhakta,et al.  Use of botulinum toxin in stroke patients with severe upper limb spasticity. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[40]  U. Moritz,et al.  Electromyographic studies of peripheral nerve block with phenol. , 2019, Scandinavian journal of rehabilitation medicine.

[41]  CHARLENE B. CALDWELL,et al.  Evaluation and Treatment of the Upper Extremity in the Hemiplegic Stroke Patient , 1969, Clinical orthopaedics and related research.

[42]  M. Botte,et al.  Time course of muscle atrophy and recovery following a phenol‐induced nerve block , 1996, Muscle & nerve.

[43]  S. Fahn,et al.  Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. , 1996, Archives of neurology.

[44]  M. Hoffer,et al.  Phenol nerve block in the treatment of acquired spastic hemiplegia in the upper limb. , 1973, The Journal of bone and joint surgery. American volume.

[45]  D. Halpern.  Histologic studies in animals after intramuscular neurolysis with phenol. , 1977, Archives of physical medicine and rehabilitation.

[46]  J. S. Hecht.  Subscapular nerve block in the painful hemiplegic shoulder. , 1992, Archives of physical medicine and rehabilitation.

[47]  Symposium synopsis , 1986 .

[48]  D. Tarsy,et al.  Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. , 1996, Archives of physical medicine and rehabilitation.

[49]  D B Calne,et al.  Treatment of spasticity with botulinum toxin: A double‐blind study , 1990, Annals of neurology.

[50]  V. Mooney,et al.  Current Status of Intraneural Phenol Injections , 1969, Clinical orthopaedics and related research.

[51]  E. Fischer,et al.  Evoked nerve conduction after nerve block by chemical means. , 1970, American journal of physical medicine.

[52]  Garland De,et al.  Current uses of open phenol nerve block for adult acquired spasticity. , 1982 .

[53]  M. Barnes,et al.  The local treatment of spasticity , 1994, Bailliere's clinical neurology.

[54]  P. Nathan,et al.  Effects of phenol on nervous conduction , 1960, The Journal of physiology.

[55]  M. Hommel,et al.  [Treatment of spasticity with botulinum toxin]. , 1992, Revue neurologique.

[56]  I. Sanders,et al.  Quantifying how location and dose of botulinum toxin injections affect muscle paralysis , 1993, Muscle & nerve.

[57]  J. Katz,et al.  Peripheral nerve injections with phenol in the management of spastic patients. , 1967, Archives of physical medicine and rehabilitation.

[58]  H. Betts,et al.  Peripheral nerve block with phenol in the management of spasticity. Indications and complications. , 1967, JAMA.

[59]  M. Keenan.  Management of the spastic upper extremity in the neurologically impaired adult. , 1988, Clinical orthopaedics and related research.

[60]  M. Keenan,et al.  Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. , 1990, The Journal of hand surgery.

[61]  L. Provinciali,et al.  Disability Changes After Treatment of Upper Limb Spasticity with Botulinum Toxin , 1996 .

[62]  R. Waters,et al.  Current uses of open phenol nerve block for adult acquired spasticity. , 1982, Clinical orthopaedics and related research.

[63]  S. Smith,et al.  A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury , 2000, Clinical rehabilitation.

[64]  T. K. Das,et al.  Botulinum toxin in treating spasticity , 1989, The British journal of clinical practice.

[65]  C. O’Brien,et al.  Injection techniques for botulinum toxin using electromyography and electrical stimulation , 1997, Muscle & nerve. Supplement.

[66]  C Tardieu,et al.  Treatment of Spasticity by Injection of Dilute Alcohol at the Motor Point or by Epidural Route: Clinical extension of an experiment on the decerebrate cat , 1968, Developmental medicine and child neurology.